Edinburgh: Vaccine against Rhodococcus equi in horses

Licensing opportunity | Collaboration opportunity

Scientists at Edinburgh University have identified a target and a vaccine candidate for the treatment of Rhodococcus equi, which is recognised as the cause of a debilitating and potentially fatal bronchopneumonia affecting horses worldwide.

One of the most challenging issues facing equine farms is the early diagnosis and treatment of R. equi infection in horses, and their management to reduce the risk of repeat infection.

Through molecular and genomic analysis of R. equi, the mechanism of how the bacteria causes infection has been elucidated. Furthermore, a drugable target has been identified, which has led to the development of several methods of treatment.

Subsequent ex vivo studies have shown that by using the treatments it is possible to prevent attachment of the R. equi pathogen to the host cell, and thus prevent the onset of the disease. These treatments include an IgG monoclonal antibody and a peptide vaccine candidate.

A UK patent, “Vaccine to treat Rhodococcus equi infections” was filed with a priority date of 11th November 2009. The university is seeking partners to help commercialise the technology via licensing and collaborative research.

For more information, visit the project’s page at: http://www.university-technology.com/details/method-of-treatment-of-rhodococcus-equi-in-horses